«‹1234567»Seite
8 articles with references, page 1 of 8

Review article

Cutaneous Side Effects of New Antitumor Drugs: Clinical Features and Management

Dtsch Arztebl Int 2012; 109(8): 133-40; DOI: 10.3238/arztebl.2012.0133

Gutzmer, R; Wollenberg, A; Ugurel, S; Homey, B; Ganser, A; Kapp, A

1. Salomon DS, Brandt R, Ciardiello F, Normanno N: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19: 183–232. CrossRef MEDLINE
2. Potthoff K, Hofheinz R, Hassel JC, et al.: Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion. Ann Oncol 2011; 22: 524–35. CrossRef MEDLINE
3. Wollenberg A, Kroth J, Hauschild A, Dirschka T: Hautreaktionen unter EGFR-Inhibitoren – Klinik und Management. Dtsch Med Wochenschr 2010; 135: 149–54. CrossRef MEDLINE
4. Gutzmer R, Becker JC, Enk A, et al.: Management kutaner Nebenwirkungen von FGFR-Inhibitoren: Empfehlungen eines deutschen Expertengremiums für den primär behandelnden Arzt. J Dtsch Dermatol Ges 2011; 9: 195–203. CrossRef MEDLINE
5. Wollenberg A, Moosmann N, Klein E, Katzer K: A tool for scoring of acneiform skin eruptions induced by EGF receptor inhibition. Exp Dermatol 2008; 17: 790–2. CrossRef MEDLINE
6. Eames T, Kroth J, Flaig MJ, Ruzicka T, Wollenberg A: Perifollicular xanthomas associated with epidermal growth factor receptor inhibitor therapy. Acta Derm Venereol 2010; 90: 202–3. CrossRef MEDLINE
7. Eames T, Grabein B, Kroth J, Wollenberg A: Microbiological analysis of epidermal growth factor receptor inhibitor therapy-associated paronychia. J Eur Acad Dermatol Venereol 2010; 24: 958–60. CrossRef MEDLINE
8. Wollenberg A, Staehler M, Eames T: Kutane Nebenwirkungen der Multikinaseinhibitoren Sorafenib und Sunitinib. Hautarzt 2010; 61: 662–7. CrossRef MEDLINE
9. Degen A, Alter M, Schenck F, et al.: Das Hand-Fuß-Syndrom als Nebenwirkung der medikamentösen Tumortherapie – Klassifikation und Management. J Dtsch Dermatol Ges 2010; 8: 652–61. CrossRef MEDLINE
10. Farr KP, Safwat A: Palmar-plantar erythrodysesthesia associated with chemotherapy and its treatment. Case Rep Oncol 2011; 4: 229–35. CrossRef MEDLINE
11. Kang YK, Lee SS, Yoon DH, et al.: Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study. J Clin Oncol 2010; 28: 3824–9. CrossRef MEDLINE
12. Wolf SL, Qin R, Menon SP, et al.: Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5. J Clin Oncol 2010; 28: 5182–7. CrossRef MEDLINE
13. Arnault JP, Wechsler J, Escudier B, et al.: Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J Clin Oncol 2009; 27: e59–e61. CrossRef MEDLINE
14. Degen A, Satzger I, Voelker B, et al.: Does basal cell carcinoma belong to the spectrum of sorafenib-induced epithelial skin cancers? Dermatology 2010; 221: 193–6. CrossRef MEDLINE
15. Robert C, Arnault JP, Mateus C: RAF inhibition and induction of cutaneous squamous cell carcinoma. Curr Opin Oncol 2011; 23: 177–82. CrossRef MEDLINE
16. Chapman PB, Hauschild A, Robert C, et al.: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507–16. CrossRef MEDLINE
17. Kahler KC, Hauschild A: Hautveränderungen durch „targeted therapies“ bei onkologischen Patienten: Kutane Nebenwirkungen zielgerichteter Therapie bei onkologischen Patienten. Hautarzt 2009; 60: 433–40. MEDLINE
18. Schad K, Baumann CK, Zipser MC, et al.: Mitogen-activated protein/extracellular signal-regulated kinase kinase inhibition results in biphasic alteration of epidermal homeostasis with keratinocytic apoptosis and pigmentation disorders. Clin Cancer Res 2010; 16: 1058–64. CrossRef MEDLINE
19. Trefzer U, Hofmann M, Sterry W: Kutane Nebenwirkungen klinisch relevanter Zytokintherapien. Dtsch Med Wochenschr 2003; 128: 1782–7. MEDLINE
20. Beck KE, Blansfield JA, Tran KQ, et al.: Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006; 24: 2283–9. CrossRef MEDLINE
21. Downey SG, Klapper JA, Smith FO, et al.: Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 2007; 13: 6681–8. CrossRef MEDLINE
22. Hodi FS, O’Day SJ, McDermott DF, et al.: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711–23. CrossRef MEDLINE
23. Kahler KC, Hauschild A: Behandlung und Nebenwirkungsmanagement des metastasierten Melanoms mit CTLA-4-Antikörpern. J Dtsch Dermatol Ges 2011; 9: 277–86. MEDLINE
24. Jaber SH, Cowen EW, Haworth LR, et al.: Skin reactions in a subset of patients with stage IV melanoma treated with anti-cytotoxic T-lymphocyte antigen 4 monoclonal antibody as a single agent. Arch Dermatol 2006; 142: 166–72. CrossRef MEDLINE